Eureka Therapeutics to Present at 6th Annual Immuno-Oncology 360° Conference
Tags:
Immuno-Oncology
EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that President and CEO Dr. Cheng Liu will be presenting at the 6th Annual Immuno-Oncology 360° Conference (IO360°) in New York on February 27, 2020.
Dr. Liu will be presenting the use of Eureka’s novel antibody-TCR receptor (ARTEMIS® T cell) that has been engineered with a proprietary human TCR-mimic antibody to target an alpha fetoprotein (AFP)-peptide/HLA-A2 complex on HCC cancer cells.
Presentation Details
Title: Innovation Hour: New Scientific Frontiers in Cell Therapies for Solid Tumors
Speaker: Dr. Cheng Liu, President and CEO
Date: Thursday, February 27, 2020
Program: Cell and Gene Therapy Day, Track B
Time: 10:40 – 11:40 a.m. EST
About Eureka Therapeutics, Inc.
Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® AbTCR T cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of multiple solid and hematologic tumors. ET140202, the Company’s lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC).
Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.
Contacts
Investors Eureka Therapeutics, Inc. Natalie Liu Investor Relations 510-722-8720 IR@eurekainc.com
Media KKH Advisors Kimberly Ha 917-291-5744 kimberly.ha@kkhadvisors.com
Investors Eureka Therapeutics, Inc. Natalie Liu Investor Relations 510-722-8720 IR@eurekainc.com
Media KKH Advisors Kimberly Ha 917-291-5744 kimberly.ha@kkhadvisors.com
